

Pfizer Document Dump Shows Doctor with Ties to Gates Foundation Deleted Trial Participant's Vaccine Injury

By <u>Michael Nevradakis</u> Global Research, May 19, 2022 <u>Children's Health Defense</u> 18 May 2022 Region: USA Theme: Law and Justice, Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), click here.

Visit and follow us on <u>Instagram</u>, <u>Twitter</u> and <u>Facebook</u>. Feel free to repost and share widely Global Research articles.

An<u>80,000-page cache</u> of Pfizer-BioNTech COVID-19 vaccine documents released by the U.S. Food and Drug Administration (FDA) sheds light on Pfizer's extensive vaccine trials in <u>Argentina</u>, including the unusually large size of the trials and the story of a trial participant whose vaccine reaction was "disappeared."

The <u>case of Augusto Roux</u> in Argentina suggests that in at least one instance, a trial participant whose symptoms were determined to be connected to the <u>COVID-19</u> vaccine was later listed, in official records, as having experienced adverse events that were not related to the vaccination.

Vaccine trials in Argentina also appear to have glossed over adverse events suffered by other trial participants, and the potential connection between the adverse events and the vaccine.

The FDA on May 2 released the latest cache of documents, which pertain to the Emergency Use Authorization of Pfizer's vaccine, as part of a <u>court-ordered</u> disclosure schedule stemming from an expedited Freedom of Information Act <u>request</u> filed in August 2021.

<u>As previously reported by The Defender</u>, the documents included Case Report Forms from Pfizer COVID vaccine trials in the U.S., and the "<u>third interim report</u>" from BioNTech's trials conducted in Germany, both of which listed adverse events sustained by participants in the U.S. and German trials.

Many of these adverse events were indicated as being "unrelated" to the vaccines — even in instances where the patients were healthy or otherwise had no prior medical history related to the injuries they sustained. Story of 'disappeared patient' goes public

Several <u>bloggers</u> and <u>online investigators</u> called into question various aspects of the Argentine vaccine trials, pointing out the number of participants in the Argentine trials dwarfed that of other, typically smaller trials at other locations in different countries.

They also pointed out the large number of participants appeared to have been recruited to the trial in a remarkably short time, and questioned the connections between one of the key figures of the Argentine trial to vaccine manufacturers, <u>Big Pharma</u> and the <u>Bill & Melinda</u> <u>Gates Foundation</u>.

The large number of trial participants in Argentina may be related to the fact that the trial appears to have been held simultaneously in <u>26 hospitals</u>.

The large number of participants is revealed in <u>another</u> of the documents released this month, where on page 2,245, the list of randomized participants at trial site 1231 begins, while on page 4,329, the list of participants at trial site 4444 begins.

<u>Site 1231</u> refers to the main trial site location and 4444 (<u>page 24</u>) most likely refers to the disparate hospitals participating in the trial outside the main location.

Commenting on the revelation, blogger David Healy wrote:

"About 5,800 volunteers were enrolled, half getting the active vaccine. This is almost 4 times more than the next largest centre in this trial.

"Amazingly 467 doctors were almost instantly signed up and trained as assistant investigators in the study."

In all, <u>4,501 patients participated</u> in the Argentine trials, representing 10% of all Pfizer trial participants worldwide.

Complete information about adverse events during this extensive trial in Argentina does not appear to have been released as of this writing.

However, Roux's experience has since become public.

Roux, often referred to as the "disappeared" patient, volunteered for the trial (volunteer number 12312982) and received his first dose of the Pfizer vaccine on Aug. 21, 2020.

<u>According to</u> Healy, Roux "felt pain and swelling in his arm right after the injection. Later that day he had nausea, difficulty swallowing, and felt hungover."

After a series of symptoms, Roux — during a clinical trial visit on Aug. 23, 2020 — was classified as experiencing a "toxicity grade 1 adverse effect."

He nevertheless received his second dose on Sept. 9, 2020.

According to Healy:

"On the way home by taxi, he started feeling unwell. At 19:30, he was short of breath, had a burning pain in his chest and was extremely fatigued. He lay on his bed and fell asleep. He woke up at 21:00 with nausea and fever (38-39 C) and was unable to get out

of bed due to the fatigue.

"Over the next two days, he reports a high fever (41 C) and feeling delirious.

"On September 11, he was able to get out of bed and go to the bathroom when he observed his urine to be dark (like Coca-Cola). He felt as if his heart expanded, had a sudden lack of breath and fell unconscious on the floor for approximately 3 hours.

"Once he recovered, he felt tired, was uncomfortable, had a high heart rate on minor movement, was dizzy when changing posture. He had a chest pain which radiated to his left arm and back."

On Sept. 12, 2020, Roux was admitted to the Hospital Alemán, where he stayed for two days. It was initially believed he had COVID-19, but he tested negative for the virus. His symptoms also were found to not correspond with viral pneumonia.

After a series of X-rays, CT scans and urine tests, Roux was discharged Sept. 14, 2020, after being diagnosed with an adverse reaction — specifically, an unequivocal pericardial effusion — to the coronavirus vaccine (high probability), according to his <u>discharge summary</u>.

Doctor who altered Roux's record had ties to Gates, NIH, Big Pharma

However, on Sept. 17, <u>Dr. Fernando Polack</u>, Pfizer's lead investigator for the Argentine trials according to a Pfizer <u>document</u> released in December 2021, <u>reported</u> in Roux's record that his "hospitalization was not related to the vaccine."

Even after Roux's discharge, his health difficulties continued. As reported by Healy:

"On November 13 [2020], he had negative IgG and IgM SARS COV-2 (QML technique), which is unusual post vaccine.

"On February 24, 2021, a liver scan showed a minor degree of abnormality. In March 2021 and February 2022, his liver enzymes remained abnormal."

Ultimately, Roux lost 14 kilograms (30.8 pounds) in a period of three to four months, and continued to suffer from fever and bouts of breathlessness for several months afterward.

Polack, who reported Roux's hospitalization as unrelated to the vaccination, is known for his close ties with various vaccine manufacturers, pharmaceutical companies and the Bill & Melinda Gates Foundation.

For instance, he is listed as the lead author in a Dec. 31, 2020, New England Journal of Medicine (NEJM) <u>article</u> on the purported efficacy of the Pfizer COVID-19 vaccine.

According to Healy, Polack also appears to be the founder of <u>iTRIALS</u>, a trial site management company, and another organization located at the same physical headquarters, the <u>Fundación INFANT</u>.

Healy wrote:

"When COVID struck Argentina, [Polack] and his Fundación became involved in a trial of immune plasma, taken from patients who had recovered from COVID, given to patients who had recently acquired the disease. "In May 2020 he speculated that this would make COVID like an ordinary cold, and the Gates Foundation would offer financial support. He used high-profile press conferences to disseminate his exciting message."

The conclusion of the <u>study</u> published in the NEJM following the plasma study reads:

"Funded by the Bill and Melinda Gates Foundation and the Fundación INFANT Pandemic Fund; Dirección de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163."

According to Healy,

"[a] subsequent<u>systematic review and meta-analysis</u> failed to confirm these findings, noting 'very serious imprecision concerns.'"

Healy pointed out that Polack, in his NEJM <u>disclosure statement</u>, did not indicate any conflict of interest or financial interest in the COVID-19 vaccine trials in Argentina, but:

"Polack reported grants from Novavax and personal fees from Janssen, Bavarian Nordic A/S, Pfizer, Sanofi, Regeneron, Merck, Medimmune, Vir Bio[technology], Ark Bio, Daiichi Sankyo outside the submitted work.

"At least eight of these companies are engaged in RSV vaccine research in babies and pregnant women. Fernando has mentioned a combined RSV, flu and COVID vaccine."

And, in relation to Polack's relationship with the Bill & Melinda Gates Foundation, Healy reported:

"[Polack] also doesn't mention his extensive financial involvement with the Bill & Melinda Gates Foundation. This organization supports industry vaccine trials including Covid and RSV. Fernando is heavily involved through his <u>Gates-sponsored</u> Fundación INFANT in Buenos Aires in RSV trials and research.

"Gates sunk \$82,553,834 into Novavax's RSV vaccine ResVax which was<u>shown to be</u> ineffective in clinical trials in pregnant women."

Polack's own bio from a 2017 medical conference states

"[h]is work is funded by the Bill & Melinda Gates Foundation, the National Institutes of Health [NIH], the Thrasher Research Fund, the Optimus Foundation and other international organizations."

That same year, Polack <u>testified</u> at an FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, where he "acknowledged having financial interests in or professional relationships with some of the affected firms identified for this meeting, namely Janssen [producer of the Johnson & Johnson COVID vaccine], <u>Novavax</u>, and Bavarian Nordic."

According to Dr. Joseph Mercola, Polack "also happens to be a consultant for the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC)," and "a current adjunct professor at Vanderbilt University in Tennessee." Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Michael Nevradakis, Ph.D., is an independent journalist and researcher based in Athens, Greece.

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Michael Nevradakis</u>, <u>Children's Health Defense</u>, 2022

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Michael Nevradakis

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca